Table 3. . Immunotherapy treatment toxicity.
Toxicity | Number (% of total cohort) | Number with eosinophilia (% of column 2) |
---|---|---|
Any grade | 66 (46.6) | 19 (28.7) |
Grade 3 or 4 | 15 (10.5) | 3 (20) |
Immune related adverse events occurred in 47% of patients, with 10% experiencing severe (grade 3 or 4) toxicity. There was a significant association found between eosinophilia on treatment and the development of toxicity of any grade (p = 0.042), but not with severe toxicity.